Almost all prostate cancer patients become resistant to therapy that blocks androgen-mediated cell proliferation. The key to this resistance may lie in expression of the androgen receptor itself.

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...

almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling ...

Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...

DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...

Results from the phase 3 PEACE-3 study found that a combination therapy showed higher benefits for patients with bone ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

Explore our latest breakthroughs in metastatic prostate cancer research. Learn more about our innovative pipeline today! @ ...